CLAIMS

1. An immediate-release pharmaceutical composition containing ketoprofen lysine salt (KLS) having a particle size distribution with a d(0.9) comprised between 150 µm and 250 µm and a d(0.5) greater than 65 µm as the active principle, and mannitol wherein the ratio of ketoprofen lysine salt to mannitol is from 100:100 to 100:250, wherein the immediate-release pharmaceutical composition is in the form of tablet, and wherein the pharmaceutical composition further comprises at least one superdisintegrant.

2. The immediate-release pharmaceutical composition according to claim 1, wherein the mannitol has a particle size distribution with maximum of 35% greater than 150 µm and/or minimum of 70% greater than 75 µm.

3. The immediate-release pharmaceutical composition according to claim 1 or 2, wherein said at least one superdisintegrant is present in an amount ranging from 25 to 50%, preferably from 30 to 45% and more preferably from 35 to 40% by weight of the amount of ketoprofen lysine salt.

4. The immediate-release pharmaceutical composition according to any one of the preceding claims, wherein said at least one superdisintegrant is selected from a group comprising crospovidone, croscarmellose, sodium starch glycolate, pregelatinized starch and mixtures thereof, preferably crospovidone.

5. The immediate-release pharmaceutical composition according to any one of the preceding claims, further comprising at least one lubricant and/or at least one glidant.

6. The immediate-release pharmaceutical composition according to claim 5, wherein said at least one lubricant is present in an amount ranging from 0 to 4.0%, preferably from 1.5 to 2.5% and more preferably from 1.75 to 2.25% by weight of the composition and/or said at least one glidant is present in an amount ranging from 0 to

2.0%, preferably from 0.5 to 1.5% and more preferably from 0.75 to 1.25% by weight of the composition.

7. The immediate-release pharmaceutical composition according to claim 5 or 6, wherein said at least one lubricant is selected from a group comprising magnesium stearate, stearic acid, talc, sodium laurylsulfate, sodium stearyl fumarate, glyceryl behenate and mixtures thereof, preferably sodium laurylsulfate and sodium stearyl fumarate.

8. The immediate-release pharmaceutical composition according to claim 5 or 6, wherein said at least one glidant is selected from a group comprising colloidal silica, talc, stearic acid and mixture thereof, preferably colloidal silica.

9. An immediate-release pharmaceutical composition according to any one of the preceding claims, obtainable by direct compression with a tableting strength from 7 to 15 kN, preferably from 7 to 10 kN.

10. A process for the preparation of an immediate-release pharmaceutical composition according to any one of the preceding claims, comprising the following steps:

a) providing ketoprofen lysine salt particles having a particle size distribution with a d(0.9) comprised between 150 µm and 250 µm and a d(0.5) greater than 65 µm, and mannitol wherein the ratio of ketoprofen lysine salt to mannitol is from 100:100 to 100:250;

b) mixing the ingredients of step a) in a suitable mixer to achieve a homogeneous mixture;

c) mixing the blend of step b) with at least one superdisintegrant, and/or at least one lubricant, and/or at least one glidant until a homogeneous powder is obtained;

d) compressing the powder mixture of step c) into a tablet;

e) optionally coating the tablet of step d).